Bayer's Eylea approved by NICE for myopic choroidal neovascularisation

Pharmaceutical Company Product News

Bayer has announced that its vision therapy Eylea has been recommended for routine NHS use by the National Institute for Health and Care Excellence (NICE).

The UK regulator has endorsed Eylea for use among NHS patients in England and Wales in the treatment of visual impairment due to myopic choroidal neovascularisation, based on its strong performance in clinical trials.

“Bayer's Eylea has been recommended by NICE as a treatment for visual impairment due to myopic choroidal neovascularisation.“

Phase II studies showed that a single initial injection of Eylea in patients with myopic choroidal neovascularisation delivered sustained and clinically meaningful visual improvements over a 48-week period.

Lars Bruening, chief executive of Bayer in the UK and Ireland, said: "We are pleased that NICE has recognised the value of Eylea and the benefits that it can bring to patients and the clinical community."

The drug has already been made available in the UK for the treatment of wet age-related macular degeneration and visual impairment due to macular oedema or diabetic macular oedema.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

See all the latest jobs in Pharmaceutical
Return to news